Serum DNA Microsatellites as Surrogate Genetic Markers of Breast Cancer Progression
Abstract
The main objective of the study is the assessment of microsatellite markers with loss of heterozygosity (LOH) in serum, bone marrow (BM), and primary tumor. We will also be investigating circulating tumor cells in blood in this study. In our last report, we demonstrated the presence of LOH in the serum and BM of early stage breast cancer patients, found a significant concordance with those present in the primary tumor, and correlated the detection of serum LOH to primary tumors with increased proliferation indices and patients with advancing stage of disease. However, we were instructed by the Office of Regulatory Compliance and Quality, U.S. Army Medical Research and Materiel Command (the Office) in June of 2002 to discontinue our research work because of inadequacy in our Institutional Review Board approved patient inform consent documentations. We regret to report that there has been no progress since the notice from the Office. Instead, we have focused on making revisions, amendments, and submissions to both our Internal Review Board and the Office for approval on the protocol and consent form to comply with the Office's recommendations.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2003
- Accession Number
- ADA424571
Entities
People
- Dave S. Hoon